Eyebot, a groundbreaking startup offering a speedy 90-second vision test kiosk, has successfully raised $20 million in Series A funding, providing doctor-verified glasses prescriptions.
Founded in 2021 and based in Boston, Eyebot is transforming the way individuals access vision care by removing traditional barriers like appointment delays, limited accessibility, intricate insurance processes, and high costs.
Their innovative kiosks, strategically located in malls, universities, retail stores, pharmacies, grocery chains, schools, and airports, provide users with a complimentary 90-second vision test. Each test generates a prescription that is meticulously reviewed and approved by licensed eye doctors, guaranteeing fast, convenient, and trustworthy prescriptions.
This latest funding round, which elevates Eyebot’s total funding to over $30 million, follows the startup’s successful seed round of $6 million raised in June 2024. Since then, Eyebot has conducted more than 45,000 complimentary vision tests and aims to surpass half a million annually.
“Since our seed round, the transformation has been remarkable. We’ve progressed from piloting to forming partnerships with some of the largest companies in the U.S., deploying kiosks nationwide, and delivering tens of thousands of vision tests,” shared Matthias Hofmann, co-founder and CEO of Eyebot, in an interview with TechCrunch. “Our revenue is growing, our team has doubled, and most importantly, we have demonstrated that our model works: consumers are utilizing Eyebot, doctors are validating the results, and retailers are thrilled with the increased foot traffic.”
What distinguishes Eyebot, according to Hofmann, is its unique blend of convenience and medical credibility. Every test is supervised by a doctor, and all prescriptions are issued under clinical oversight. If any test results indicate unusual findings, patients are promptly referred for comprehensive in-person exams. This combination of speed and clinical integrity builds consumer trust.
“In our mall locations, we’ve seen an unexpected interest from parents with children,” Hofmann noted. “They often stop between shopping trips, use Eyebot—sometimes even while holding their kids’ hands—and walk away with a prescription in just a few minutes.”
Tech and VC heavyweights join the Disrupt 2025 agenda
Don’t miss the chance to learn from industry leaders like Netflix, ElevenLabs, and Sequoia Capital at the 20th anniversary of TechCrunch Disrupt. Get your ticket now and save up to $600+ before prices increase.
Tech and VC heavyweights join the Disrupt 2025 agenda
Join top industry voices from Netflix, ElevenLabs, and Wayve at TechCrunch Disrupt 2025. Don’t miss out—grab your ticket now and save up to $675 before prices go up!
|
October 27-29, 2025
Convincing traditional eye care providers to adopt a technology-first approach has been challenging. Initial skepticism was prevalent, with doctors concerned about accuracy and patients doubtful of the reliability of such a quick process. However, this hesitancy has diminished as providers learned that experienced doctors review every test result, many boasting over a decade of expertise.
Eyebot is just beginning its commercialization journey. Consumers receive the vision test free of charge, and if a prescription is required, a company doctor verifies it for a nominal fee. Additionally, Eyebot leases its kiosks to optical retailers, eyewear brands, and independent practices.
With the new Series A funding, the company plans to enhance its kiosk deployment and expand its workforce across product development, clinical operations, and commercial growth, as stated by the CEO.
This funding round was spearheaded by General Catalyst, with contributions from returning investors including AlleyCorp, Baukunst, Village Global, Humba Venture, Ravelin, and Ubiquity Ventures.
